Physician profile
Steven V Dill
NPI 1770732836
$1,811.81
in general payments reported to CMS, 2019-2025
19 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $29.00 · 2021: $19.43 · 2022: $16.77 · 2023: $61.25 · 2024: $118 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $1,186.83 | 2019 | |
| Teleflex LLC | $141.51 | 2025 | Barrigel |
| Astrazeneca Pharmaceuticals Lp | $65.28 | 2024-2025 | Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $52.04 | 2020-2024 | Keytruda, Lynparza |
| Novocure INC. | $51.58 | 2019-2024 | Optune |
| Siemens Medical Solutions USA, INC. | $44.67 | 2023 | Aria Radiation Therapy Management Software, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $35.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.03 | 2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.37 | 2019 | |
| Myriad Genetic Laboratories, INC. | $24.83 | 2025 | Prolaris |
| Boston Scientific Corporation | $19.74 | 2024 | Spaceoar Vue System - 10ml |
| Eisai INC. | $19.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.44 | 2019 | |
| Genentech USA, INC. | $16.94 | 2024 | Avastin, Tecentriq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.58 | 2023 | Ultomiris |
| Foundation Medicine, INC. | $13.51 | 2019 | |
| Amgen INC. | $13.29 | 2019 | |
| Seagen INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.